Member Info for BuenaVista

Nah. The frustrating bit is that every decent bit of news means the SP falls.

I get it now and it's really neat. For chemistry nerds:

When the substrate is cleaved by FAP in the TME, the 'self-immolative linker' part becomes an area of delocalized electrons (electrons not located/associated with particular atoms) and that weakens the bond to the warhead and the linker falls off. That happens in the TME, releasing the warhead there.

It's stated in the conclusions.

Go gently on yuyus. He bought on Tuesday so is understandably miffed that there's been no 5000% SP increase yet.

@nursesteve, er, no. I'm saying that if the quoted sell price is 74 and the quoted buy price is 76 and the trade is at 75, then the algorithm gets confused. But if there are trades above 75 and none much below 75 then 75 would be a sell and if the converse were the case - trades below 75 and trades not much above 75 then it would be a buy.

The algorithm is dumb and just assigns buy/sell according to above/below the midprice.

We've been though this many, many times on here. Don't look at the buy/sell designations, compare the prices to the QUOTED spread.

I truly don't understand how the self-immolative linker gets split off from the warhead in the TME. From my own research, I get the 'spontaneous' bit. But why in the TME and before/after the FAP cleavage of the pre|CISION linker and not at any time before/after that in the plasma? Anyway, I hope CC will take my question on the 30th.

"Self-immolative elimination occurs when a molecular system undergoes a spontaneous and irreversible disassembly into its constituent fragments through either an electronic cascade, via an elimination pathway or, alternatively, where self-immolation is achieved through a cyclisation–elimination event." https://pubs.rsc.org/en/content/articlehtml/2022/py/d2py00414c

It's the midprice, so the simplistic algorithm gets confused. Are the other trades above (in which case 75 is a sell) or below (in which case 75 is a buy)?

Comforting to know. Come back at the end of the month when theSP is 86p. Byeeee

RNS could say poster abstract will be on website tomorrow.

Sep 24, 11:15am

https://informaconnect.com/cell-therapy-bioprocessing/speakers/sung-hyun-choi-phd/#development-of-emerging-cell-gene-therapies_revolutionizing-substantive-off-the-shelf-msc-therapeutics-for-restoring-immune-balance

SP crossed the 20 and 200 day moving averages today after crossing the 50 day moving average yesterday.

You know what this means...

Another RNS in the morning...

OK Trigger, whatever

PL on the hopium again

Trader

Nice excuses guys. No doubt there is a rational explanation for why something released near th end of Q3 should be presented as something from nearing the end of Q2.

Did CC really say ...on 11 September ..."As we approach the second half of 2024"? 🫤

I can see an AI romance developing between these two.

So why would a company spend £2bn on a licence deal when they could buy the whole company for £300m, £500m, £1bn?

But Avacta has a MCap less debt of £220m. That is back of the sofa money for big farmer. It strikes me these £bn licence deals being bandied about are pure fantasy.

Avacta has a MCap of £250m and a SP of 70p, with some debt.

Why licence AVA6000 for £2-3bn? Even at £2bn, big pharma could buy the whole company with some pocket cash for 550p a share. PIs would bite their hands off for that.